# Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma

> **NCT05222529** · PHASE2 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 42 (estimated)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Glycopyrronium bromide 25ug
- **DRUG:** Placebo
- **DRUG:** Glycopyrronium bromide 12.5ug

## Key facts

- **NCT ID:** NCT05222529
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-29
- **Primary completion:** 2027-07-30
- **Final completion:** 2027-08-30
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05222529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05222529, "Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05222529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*